Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases. The company is centered on complement-targeting science, with a portfolio of monoclonal antibodies and fusion proteins designed to selectively modulate immune pathways involved in disease activity. Its lead programs include claseprubart, an engineered antibody designed to inhibit the active C1s complement protein, and DNTH212, a bifunctional fusion protein that combines immune-cell targeting with suppression of B-cell signaling. Dianthus Therapeutics Inc. is advancing these candidates for conditions such as generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. The company’s role in the market is to develop differentiated antibody-based treatments aimed at patients with serious immune-mediated disorders that have limited therapeutic options.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Marino Garcia M.B.A.

Employees

78

Headquarters

New York, NY, United States

Website

dianthustx.com